Shanthi is a contributor to InvestorPlace.com and works as a Staff Writer with Benzinga. Equipped with a Bachelor鈥檚 degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors.
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.
Reverse stock splits are not that common and often are associated with some trouble brewing at the company. Therefore, one must do a thorough study before deciding what to do what with the stock of a company that just announced a reverse split.
All meme stocks may not be sound investment options. A close scrutiny of these stocks can help to zero in on investment-worthy candidates from among these stocks.
Once the bear market runs its course, semiconductor stocks could lead the market recovery and here are a few bargain buys offering biggest upside potential.
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.
Reverse stock splits are not that common and often are associated with some trouble brewing at the company. Therefore, one must do a thorough study before deciding what to do what with the stock of a company that just announced a reverse split.
Some stocks currently trading in penny stock territory have unique advantages that makes it worthwhile to overlook the inherent risk involved in investing in these stocks.
Recession talks are growing louder amid worsening in economic fundamentals. Rising inflation accompanied by slow growth is portending the probability of stagflation -- a form of recession.
Ark Invest holds these growth stocks in its actively-managed ETFs. These Cathie Wood stocks are now available at dirt cheap prices.
Apple stock has fared relatively better than the tech sector amid the market sell-off, but has underperformed the broader market. Technically and fundamentally, AAPL stock could be well positioned for a bounce-back.
Nio could be in for a strong rebound, when cautious investors take cognizance of the fundamental prospects amid the anticipated improvement in economic and geopolitical situation.
Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way.
It could be a 鈥渘ever-before, never-after opportunity鈥� to buy into these biotech stocks that trade at very attractive valuations.
The worst may be behind for electric vehicle stocks as manufacturers emerge out of the crises induced by geopolitical tensions .
Cybersecurity stocks are poised to outperform the broader tech sector and the oversold nature of some of these give an added reason to buy them.
These commercial-stage electric vehicle stocks to buy have a history of strong execution and solid balance sheets.
The stock market is presently in shambles and a resolution isn鈥檛 close at sight. What better way to insulate yourselves against the volatility than to invest in oversold dividend-paying stocks.
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.
Despite fears of a semiconductor cycle correction, the industry is poised to growth strongly, thanks to solid uptake of memory chips and 5G migration.
Beaten-down EV stocks can draw inspiration from new product launches scheduled for the year. This will serve to accelerate EV adoption.
EVgo stock could get moving if the company can capitalize on the vast opportunity provided by it many partnerships.
Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of blockbuster products.
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.
RIVN stock is overvalued even with the steep drop from its post-IPO highs. Redemption isn't at sight at least in the near term.
CarMax's fourth quarter came as a disappointment, with earnings trailing estimates. Don't jump into KMX stock for now.
After multiple delays Tesla's Cybertruck may finally be on roads by next year. It remains to be seen whether the EV giant keeps the timeline this time around.
Key to successful investing is identifying stocks of high-growth businesses that are available at affordable prices. With the recent market downturn, some of the tech plays are once again turning attractive.
Origin Agritech's rally on the back of contract wins for its fortified corn alone cannot guarantee redemption for the stock. The fundamental story of the genetically-modified crop and seed manufacturer is far from convincing.
As the U.S. economy stutters, COST stock could end the search for recession-proof stocks, which has built up a reputation as a defensive play.
Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belonging to the sector seeing some of these make-or-break catalysts.
Some positive recent developments and cheap valuation could help reverse investor sentiment toward SPOT stock.
Nio reported quarterly results that could not allay all fears that investors were harboring. All the same, the management commentary on the earnings call provided enough and more reasons for staying invested in the stock
Fundamental soundness and aggressive market expansion opportunities pursued by Nvidia add credence to the bullish thesis on this diversified tech play.
NIO stock鈥檚 recent recovery should offer hopes for its patient investors who have stayed loyal to the stock. The fourth-quarter earnings could help the stock build on, or to the minimum, sustain the recent momentum it has picked up.
Several risks that are currently in play, including the crisis in Eastern Europe, resurgence of the Covid-19 pandemic in China and the U.S. Federal Reserve鈥檚 monetary policy tightening, have made it prudent to revisit some of the time-tested safe haven investing ideas that can offer protection in times of these uncertainties.
PLTR stock has now lost about three-fourth of its peak valuation. Both external and internal factors have played a role in its sell-off.
Some high-quality China stocks are selling at bargains. The space is definitely worth taking a look at for those willing to ride the risk.
TSMC's chips power a slew of applications and devices and its technological leadership positions TSM stock on the superhighway of growth.
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.
NVAX stock continues to languish for want of evidence for a sustainable fundamental improvement. The 2022 revenue guidance issued by the company did stir some optimism, but investors have quickly fallen back to their guarded stance.
Lucid flagged production issues and tempered its outlook for 2022. It remains to be seen if LCID stock can overcome the near-term issues.
Moderna has to focus on the rest of its pipeline to keep MRNA stock relevant and profitable as Covid vaccine revenues taper off by 2023.
BABA stock has caused so much frustration to investors, but today's weakness could be an excellent entry point for long-term Alibaba growth.
Bitcoin has been locked in a lackluster phase since late last year. But the long-term factors are on its side, and it should grow further.
AAPL stock could defy the typically slower first half and launch into rally, thanks to plenty of new tech on tap.
Entering the third year of the pandemic, tech stocks are at crossroads. The pandemic presented them with both adversities and opportunities.
EV stocks have gotten off to a weak start in 2022, but compelling new products could serve as key catalysts to reverse sentiment.
NVAX stock may have seen a near-term bounce following the completion of filing of EUA filing with the FDA, but it may not be a buy yet.
NIO stock hasn't kept up with other EV Stocks, but that should change if it executes on its strategy and resolve production issues.
Dogecoin, once an darling among crypto investors, has retreated sharply since the middle of 2021, and the broader cryptocurrency market sell-off has served to exacerbate the weakness. Does the meme currency has in itself to turn things around?
Get Louis Navellier鈥檚 take on the news and events impacting the market, plus his top stock picks.
Your Email
